Commonly used tools to assess the probability of obstructive-coronary artery disease (CAD) were derived based on Caucasian cohorts, with their performance in China is still unknown.
Furthermore, most were established based on non-laboratory variables, contributing to the limited predictive ability to some extent. Thus, we developed and internally validated a laboratory-based model with data from a Chinese cohort of 8963 inpatients, with suspected stable chest pain, referred to catheter-based coronary angiography (CAG) from September 2007 to April 2019, and then compared the present model’s performance with the four most commonly used prediction tools, Coronary Artery Disease Consortium 1/2 Score (CAD1/2), Duke clinical score (DCS), and Diamond-Forrester score (DF).
The final model was developed by random forest method, including 8 predictors derived from 70 variables. Five-fold cross-validation was performed to evaluate the model’s prediction accuracy. In the external validation set, the present model showed a superior area under the receiver-operating curve (0.816), followed by DCS (0.66), CAD2 (0.61), CAD1 (0.59) and at last DF (0.58), respectively.
Furthermore, the present model correctly classified 74.4% of obstructive-CAD patients as high-risk, and correctly classified more than one third of non-obstructive-CAD patients as low-risk.
The present model’s net reclassification improvement (NRI) showed a significant positive reclassification over CAD1 (NRI = 0.60, P < 0.001), DF (NRI = 0.59, P < 0.001), CAD2 (NRI = 0.57, P < 0.001), and DCS (NRI = 0.43, P < 0.001). Decision curve analysis demonstrated that the present model provided a larger net benefit compared with CAD1/2, DCS, and DF.
NCT 02 |
|||
| 466234 | MedKoo Biosciences | 10.0mg | EUR 390 |
TA-02 |
|||
| 530937 | MedKoo Biosciences | 100.0mg | EUR 750 |
PU-02 |
|||
| 530962 | MedKoo Biosciences | 10.0mg | EUR 250 |
PU 02 |
|||
| B5687-10 | ApexBio | 10 mg | EUR 197 |
|
Description: negative allosteric modulator of 5-HT3 receptors |
|||
PU 02 |
|||
| B5687-25 | ApexBio | 25 mg | EUR 571.2 |
PU 02 |
|||
| B5687-5 | ApexBio | 5 mg | EUR 172.8 |
PU 02 |
|||
| B5687-50 | ApexBio | 50 mg | EUR 832 |
|
Description: negative allosteric modulator of 5-HT3 receptors |
|||
TA-02 |
|||
| B1215-25 | Biovision | each | EUR 679.2 |
TA-02 |
|||
| B1215-5 | Biovision | each | EUR 222 |
TA 02 |
|||
| B4924-10 | ApexBio | 10 mg | EUR 160 |
|
Description: p38 MAPK inhibitor |
|||
TA 02 |
|||
| B4924-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 81 |
|
Description: p38 MAPK inhibitor |
|||
TA 02 |
|||
| B4924-50 | ApexBio | 50 mg | EUR 600 |
|
Description: p38 MAPK inhibitor |
|||
UCN-02 |
|||
| C4829-1 | ApexBio | 1 mg | EUR 326 |
|
Description: protein kinase C inhibitor |
|||
UCN-02 |
|||
| C4829-5 | ApexBio | 5 mg | EUR 1146 |
|
Description: protein kinase C inhibitor |
|||
UCN-02 |
|||
| 564792 | MedKoo Biosciences | 1.0mg | EUR 520 |
IMM-02 |
|||
| T25530-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: IMM-02 |
|||
IMM-02 |
|||
| T25530-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: IMM-02 |
|||
IMM-02 |
|||
| T25530-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: IMM-02 |
|||
IMM-02 |
|||
| T25530-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: IMM-02 |
|||
IMM-02 |
|||
| T25530-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: IMM-02 |
|||
UCN-02 |
|||
| T17198-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: UCN-02 |
|||
UCN-02 |
|||
| T17198-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: UCN-02 |
|||
UCN-02 |
|||
| T17198-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: UCN-02 |
|||
UCN-02 |
|||
| T17198-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: UCN-02 |
|||
UCN-02 |
|||
| T17198-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: UCN-02 |
|||
ELX-02 |
|||
| T31616-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: ELX-02 |
|||
ELX-02 |
|||
| T31616-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: ELX-02 |
|||
ELX-02 |
|||
| T31616-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: ELX-02 |
|||
ELX-02 |
|||
| T31616-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: ELX-02 |
|||
ELX-02 |
|||
| T31616-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: ELX-02 |
|||
SST-02 |
|||
| T34707-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: SST-02 |
|||
SST-02 |
|||
| T34707-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: SST-02 |
|||
SST-02 |
|||
| T34707-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: SST-02 |
|||
SST-02 |
|||
| T34707-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: SST-02 |
|||
SST-02 |
|||
| T34707-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: SST-02 |
|||
TA-02 |
|||
| T4646-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: TA-02 |
|||
TA-02 |
|||
| T4646-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: TA-02 |
|||
TA-02 |
|||
| T4646-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: TA-02 |
|||
TA-02 |
|||
| T4646-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: TA-02 |
|||
TA-02 |
|||
| T4646-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: TA-02 |
|||
UCN-02 |
|||
| HY-108262 | MedChemExpress | 1mg | EUR 872.4 |
TA-02 |
|||
| HY-100115 | MedChemExpress | 10mM/1mL | EUR 484.8 |
UCN-02 |
|||
| U006-1MG | TOKU-E | 1 mg | EUR 216.32 |
|
Description: C28H26N4O4 |
|||
UCN-02 |
|||
| U006-5MG | TOKU-E | 5 mg | EUR 756.48 |
|
Description: C28H26N4O4 |
|||
UCN-02 |
|||
| U130603 | Toronto Research Chemicals | 1mg | EUR 1800 |
|
Description: 121569-61-7 |
|||
Anti-Annexin A10 Antibody [SC06-02] |
|||
| ET1610-57 | HUABIO | 100ul | EUR 231 |
|
Description: The annexin family of calcium-binding proteins contains several family members that are characterized by a conserved core domain which binds phospholipids in a Ca2+-dependent manner, and a unique amino-terminal region which may confer binding specificity. Annexin family members have been implicated as regulators of such diverse processes as ion flux, endocytosis, exocytosis and cellular adhesion. Annexin A10, also known as ANX14 or ANXA10, is a 324 amino acid protein that contains four Annexin domains and may be involved in the regulation of cellular growth and signal transduction pathways throughout the cell. The gene encoding Annexin A10 maps to human chromosome 4, which encodes nearly 6% of the human genome and has the largest gene deserts (regions of the genome with no protein encoding genes) of all of the human chromosomes. |
|||
VX-222 |
|||
| 27053 | BPS Bioscience | 5 mg | EUR 275 |
|
Description: VX-222 is a novel, potent and selective inhibitor of non-nucleoside polymerase of the hepatitis C virus (HCV) RNA-dependent RNA polymerase, with an IC50 range of 0.94-1.2 µM. VX-222 selectively inhibits the replication of both HCV1a and HCV1b. |
|||
VX-222 |
|||
| E1KS1480 | EnoGene | 5mg | EUR 633.6 |
QX 222 |
|||
| B6565-10 | ApexBio | 10 mg | EUR 100 |
|
Description: Sodium channel blocker |
|||
QX 222 |
|||
| B6565-50 | ApexBio | 50 mg | EUR 342 |
|
Description: Sodium channel blocker |
|||
VX-222 |
|||
| B2207-25 | Biovision | each | EUR 810 |
VX-222 |
|||
| B2207-5 | Biovision | each | EUR 248.4 |
QX-222 |
|||
| 574856 | MedKoo Biosciences | 10.0mg | EUR 255 |
BIBS-222 |
|||
| T26802-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: BIBS-222 |
|||
BIBS-222 |
|||
| T26802-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: BIBS-222 |
|||
BIBS-222 |
|||
| T26802-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: BIBS-222 |
|||
BIBS-222 |
|||
| T26802-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: BIBS-222 |
|||
BIBS-222 |
|||
| T26802-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: BIBS-222 |
|||
AMG-222 |
|||
| T29970-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: AMG-222 |
|||
AMG-222 |
|||
| T29970-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: AMG-222 |
|||
AMG-222 |
|||
| T29970-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: AMG-222 |
|||
AMG-222 |
|||
| T29970-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: AMG-222 |
|||
AMG-222 |
|||
| T29970-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: AMG-222 |
|||
MD-222 |
|||
| T37041-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: MD-222 |
|||
MD-222 |
|||
| T37041-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: MD-222 |
|||
MD-222 |
|||
| T37041-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: MD-222 |
|||
MD-222 |
|||
| T37041-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: MD-222 |
|||
MD-222 |
|||
| T37041-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: MD-222 |
|||
VX-222 |
|||
| HY-75800 | MedChemExpress | 10mM/1mL | EUR 241.2 |
miRZip-222 anti-miR-222 microRNA construct |
|||
| MZIP222-PA-1 | SBI | Bacterial Streak | EUR 620 |
ZNL-02-096 |
|||
| 533532 | MedKoo Biosciences | 5.0mg | EUR 850 |
OXF BD 02 |
|||
| B4918-10 | ApexBio | 10 mg | EUR 237 |
|
Description: Selective inhibitor of the first bromodomain of BRD4 |
|||
OXF BD 02 |
|||
| B4918-50 | ApexBio | 50 mg | EUR 1000 |
|
Description: Selective inhibitor of the first bromodomain of BRD4 |
|||
OXF BD 02 |
|||
| T23115-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: OXF BD 02 |
|||
OXF BD 02 |
|||
| T23115-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: OXF BD 02 |
|||
OXF BD 02 |
|||
| T23115-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: OXF BD 02 |
|||
OXF BD 02 |
|||
| T23115-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: OXF BD 02 |
|||
OXF BD 02 |
|||
| T23115-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: OXF BD 02 |
|||
ELX-02 disulfate |
|||
| T19306-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: ELX-02 disulfate |
|||
ELX-02 disulfate |
|||
| T19306-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: ELX-02 disulfate |
|||
ELX-02 disulfate |
|||
| T19306-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: ELX-02 disulfate |
|||
ELX-02 disulfate |
|||
| T19306-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: ELX-02 disulfate |
|||
ELX-02 disulfate |
|||
| T19306-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: ELX-02 disulfate |
|||
ELX-02 sulfate |
|||
| T19307-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: ELX-02 sulfate |
|||
ELX-02 sulfate |
|||
| T19307-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: ELX-02 sulfate |
|||
ELX-02 sulfate |
|||
| T19307-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: ELX-02 sulfate |
|||
ELX-02 sulfate |
|||
| T19307-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: ELX-02 sulfate |
|||
ELX-02 sulfate |
|||
| T19307-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: ELX-02 sulfate |
|||
1961358-02-0 |
|||
| TBW00994 | ChemNorm | 10mg | Ask for price |
145867-02-3 |
|||
| TBZ1279 | ChemNorm | unit | Ask for price |
ZNL 02-096 |
|||
| T41163-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: ZNL 02-096 |
|||
ZNL 02-096 |
|||
| T41163-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: ZNL 02-096 |
|||
ZNL 02-096 |
|||
| T41163-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: ZNL 02-096 |
|||
ZNL 02-096 |
|||
| T41163-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: ZNL 02-096 |
|||
ZNL 02-096 |
|||
| T41163-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: ZNL 02-096 |
|||
ELX-02 disulfate |
|||
| HY-114231B | MedChemExpress | 5mg | EUR 680.4 |
ELX-02 sulfate |
|||
| HY-114231C | MedChemExpress | 10mg | EUR 1093.2 |
Monoclonal LST1 Antibody (clone LST1/02), Clone: LST1/02 |
|||
| APR12482G | Leading Biology | 0.05mg | EUR 580.8 |
|
Description: A Monoclonal antibody against Human LST1 (clone LST1/02). The antibodies are raised in Mouse and are from clone LST1/02. This antibody is applicable in WB and IHC-P, ICC, IP |
|||
Cryptating agent 222 |
|||
| 598848 | MedKoo Biosciences | 1.0mg | EUR 460 |
Cryptating agent 222 |
|||
| T20736-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: Cryptating agent 222 |
|||
Cryptating agent 222 |
|||
| T20736-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: Cryptating agent 222 |
|||
Cryptating agent 222 |
|||
| T20736-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: Cryptating agent 222 |
|||
Cryptating agent 222 |
|||
| T20736-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: Cryptating agent 222 |
|||
Cryptating agent 222 |
|||
| T20736-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: Cryptating agent 222 |
|||
QX-222 chloride |
|||
| T23213-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: QX-222 chloride |
|||
QX-222 chloride |
|||
| T23213-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: QX-222 chloride |
|||
QX-222 chloride |
|||
| T23213-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: QX-222 chloride |
|||
QX-222 chloride |
|||
| T23213-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: QX-222 chloride |
|||
QX-222 chloride |
|||
| T23213-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: QX-222 chloride |
|||
Monoclonal TRAF2 Antibody (aa205-222, clone 33A1293), Clone: 33A1293 |
|||
| AMM01751G | Leading Biology | 0.05mg | EUR 580.8 |
|
Description: A Monoclonal antibody against Human TRAF2 (aa205-222, clone 33A1293). The antibodies are raised in Mouse and are from clone 33A1293. This antibody is applicable in WB and IHC-P |
|||
XMIR-222 RNA oligo miRNA-222-3p with Xmotif |
|||
| XMIR-222 | SBI | 10 rxn | EUR 379 |
JH-XI-10-02 |
|||
| 407891 | MedKoo Biosciences | 5.0mg | EUR 550 |
JBJ-03-142-02 |
|||
| 462088 | MedKoo Biosciences | 10.0mg | EUR 409 |
JBJ-04-125-02 |
|||
| 558957 | MedKoo Biosciences | 500.0mg | EUR 3650 |
JH-VIII-157-02 |
|||
| T15612-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: JH-VIII-157-02 |
|||
JH-VIII-157-02 |
|||
| T15612-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: JH-VIII-157-02 |
|||
JH-VIII-157-02 |
|||
| T15612-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: JH-VIII-157-02 |
|||
JH-VIII-157-02 |
|||
| T15612-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: JH-VIII-157-02 |
|||
JH-VIII-157-02 |
|||
| T15612-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: JH-VIII-157-02 |
|||
RNF5 inhibitor inh-02 |
|||
| T35883-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: RNF5 inhibitor inh-02 |
|||
RNF5 inhibitor inh-02 |
|||
| T35883-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: RNF5 inhibitor inh-02 |
|||
RNF5 inhibitor inh-02 |
|||
| T35883-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: RNF5 inhibitor inh-02 |
|||
RNF5 inhibitor inh-02 |
|||
| T35883-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: RNF5 inhibitor inh-02 |
|||
RNF5 inhibitor inh-02 |
|||
| T35883-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: RNF5 inhibitor inh-02 |
|||
JBJ-03-142-02 |
|||
| T35901-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: JBJ-03-142-02 |
|||
JBJ-03-142-02 |
|||
| T35901-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: JBJ-03-142-02 |
|||
JBJ-03-142-02 |
|||
| T35901-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: JBJ-03-142-02 |
|||
JBJ-03-142-02 |
|||
| T35901-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: JBJ-03-142-02 |
|||
JBJ-03-142-02 |
|||
| T35901-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: JBJ-03-142-02 |
|||
JH-VIII-157-02 |
|||
| HY-112140 | MedChemExpress | 10mM/1mL | EUR 892.8 |
Anti-07/02/07 |
|||
| STJ501223 | St John's Laboratory | 100 µg | EUR 571.2 |
JBJ-02-112-05 |
|||
| T11713-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: JBJ-02-112-05 |
|||
JBJ-02-112-05 |
|||
| T11713-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: JBJ-02-112-05 |
|||
JBJ-02-112-05 |
|||
| T11713-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: JBJ-02-112-05 |
|||
JBJ-02-112-05 |
|||
| T11713-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: JBJ-02-112-05 |
|||
JBJ-02-112-05 |
|||
| T11713-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: JBJ-02-112-05 |
|||
JBJ-04-125-02 |
|||
| T11714-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: JBJ-04-125-02 |
|||
JBJ-04-125-02 |
|||
| T11714-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: JBJ-04-125-02 |
|||
JBJ-04-125-02 |
|||
| T11714-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: JBJ-04-125-02 |
|||
JBJ-04-125-02 |
|||
| T11714-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: JBJ-04-125-02 |
|||
JBJ-04-125-02 |
|||
| T11714-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: JBJ-04-125-02 |
|||
JH-XI-10-02 |
|||
| T13743-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: JH-XI-10-02 |
|||
JH-XI-10-02 |
|||
| T13743-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: JH-XI-10-02 |
|||
JH-XI-10-02 |
|||
| T13743-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: JH-XI-10-02 |
|||
JH-XI-10-02 |
|||
| T13743-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: JH-XI-10-02 |
|||
JH-XI-10-02 |
|||
| T13743-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: JH-XI-10-02 |
|||
WSID 02 AO LOTO |
|||
| 833773 | BRADY NV | Piece of 1 Piece(s) | EUR 14.81 |
|
Description: Description Dutch: Nood-ID-tag voor werknemers; Description French: Etiquette d’identification d’urgence pour les employés |
|||
AXMIR-222 RNA oligo anti-miRNA-222-3p with Xmotif |
|||
| AXMIR-222 | SBI | 10 reactions | EUR 379 |
MAP2K3 (Ab-222) Antibody |
|||
| 33236 | SAB | 100ul | EUR 319 |
MAP2K3 (Ab-222) Antibody |
|||
| 33236-100ul | SAB | 100ul | EUR 302.4 |
MAP2K3 (Ab-222) Antibody |
|||
| 33236-50ul | SAB | 50ul | EUR 224.4 |
BTK (Ab-222) Antibody |
|||
| 33121 | SAB | 100ul | EUR 319 |
BTK (Ab-222) Antibody |
|||
| 33121-100ul | SAB | 100ul | EUR 302.4 |
BTK (Ab-222) Antibody |
|||
| 33121-50ul | SAB | 50ul | EUR 224.4 |
BTK (Ab-222) Antibody |
|||
| E033121 | EnoGene | 100μg/100μl | EUR 255 |
|
Description: Available in various conjugation types. |
|||
MAP2K3 (Ab-222) Antibody |
|||
| E033236 | EnoGene | 100μg/100μl | EUR 255 |
|
Description: Available in various conjugation types. |
|||
MAP2K3 (Ab-222) Antibody |
|||
| E11-8139B | EnoGene | 100μg | EUR 225 |
|
Description: Available in various conjugation types. |
|||
MAPKAPK2 (Ab-222) Antibody |
|||
| E11-0677B | EnoGene | 100μg | EUR 225 |
|
Description: Available in various conjugation types. |
|||
BTK (Ab-222) Antibody |
|||
| E11-0054B | EnoGene | 100μg/100μl | EUR 225 |
|
Description: Available in various conjugation types. |
|||
FANCD2 (Ab-222) Antibody |
|||
| E11-0427B | EnoGene | 100μg/100μl | EUR 225 |
|
Description: Available in various conjugation types. |
|||
MAPK3 (pY205 / 222) Antibody |
|||
| abx333481-100ul | Abbexa | 100 ul | EUR 560.4 |
Cytokeratin 222 Pseudogene antibody |
|||
| 70R-4160 | Fitzgerald | 50 ug | EUR 467 |
|
Description: Rabbit polyclonal Cytokeratin 222 Pseudogene antibody raised against the N terminal of KRT222P |
|||
MAP2K3 (Ab-222) Antibody |
|||
| CSB-PA084775- | Cusabio | each | EUR 402 |
|
Description: A polyclonal antibody against MAP2K3 (Ab-222). Recognizes MAP2K3 (Ab-222) from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IF;WB:1:500-1:3000, IF:1:50-1:200 |
|||
MAP2K3 (Ab-222) Antibody |
|||
| CSB-PA084775-100ul | Cusabio | 100ul | EUR 379.2 |
|
Description: A polyclonal antibody against MAP2K3 (Ab-222). Recognizes MAP2K3 (Ab-222) from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IF;WB:1:500-1:3000, IF:1:50-1:200 |
|||
BTK (Ab-222) Antibody |
|||
| 8B0054 | AAT Bioquest | 50ug | EUR 368 |
|
Description: BTK (Ab-222) Antibody |
|||
FANCD2 (Ab-222) Antibody |
|||
| 8B0427 | AAT Bioquest | 50ug | EUR 368 |
|
Description: FANCD2 (Ab-222) Antibody |
|||
MAPKAPK2 (Ab-222) Antibody |
|||
| 8B0677 | AAT Bioquest | 50ug | EUR 368 |
|
Description: MAPKAPK2 (Ab-222) Antibody |
|||
MAP2K3 (Ab-222) Antibody |
|||
| 8B8139 | AAT Bioquest | 50ug | EUR 368 |
|
Description: MAP2K3 (Ab-222) Antibody |
|||
MEK1 (pS218 / 222) Antibody |
|||
| abx031877-400ul | Abbexa | 400 ul | EUR 627.6 |
MEK1 (pS218 / 222) Antibody |
|||
| abx031877-80l | Abbexa | 80 µl | EUR 343.2 |
rno-miR-222 Primers |
|||
| MP-r00149 | ABM | 150 ul / 10 uM | EUR 211.2 |
mmu-miR-222 Primers |
|||
| MPM00254 | ABM | 150 ul / 10 uM | EUR 145.2 |
hsa-miR-222 Primers |
|||
| MPH01282 | ABM | 150 ul / 10 uM | EUR 145.2 |
Phospho-ERK 1/2 (Y205/222) (7A6) Mouse Monoclonal Antibody |
|||
| EM1342-100ul | ELK Biotech | 100ul | EUR 124 |
|
Description: A Mouse Monoclonal antibody against Phospho-ERK 1/2 (Y205/222) (7A6) from Human/ Mouse/ Rat. This antibody is tested and validated for IHC |
|||
Phospho-ERK 1/2 (Y205/222) (7A6) Mouse Monoclonal Antibody |
|||
| EM1342-50ul | ELK Biotech | 50ul | EUR 74 |
|
Description: A Mouse Monoclonal antibody against Phospho-ERK 1/2 (Y205/222) (7A6) from Human/ Mouse/ Rat. This antibody is tested and validated for IHC |
|||
Monoclonal HLA-E Antibody (clone MEM-E/02), Clone: MEM-E/02 |
|||
| AMM01781G | Leading Biology | 0.05mg | EUR 580.8 |
|
Description: A Monoclonal antibody against Human HLA-E (clone MEM-E/02). The antibodies are raised in Mouse and are from clone MEM-E/02. This antibody is applicable in WB and IHC-P |
|||
Monoclonal HLA-E Antibody (clone MEM-E/02), Clone: MEM-E/02 |
|||
| AMM02314G | Leading Biology | 0.05mg | EUR 580.8 |
|
Description: A Monoclonal antibody against Human HLA-E (clone MEM-E/02). The antibodies are raised in Mouse and are from clone MEM-E/02. This antibody is applicable in WB and IHC-P |
|||
Anti-SHP1 Antibody [SR41-02] |
|||
| ET1602-19 | HUABIO | 100ul | EUR 231 |
|
Description: Tyrosine-protein phosphatase non-receptor type 6, also known as Src homology region 2 domain-containing phosphatase-1 (SHP-1), is an enzyme that in humans is encoded by the PTPN6 gene. The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. N-terminal part of this PTP contains two tandem Src homolog (SH2) domains, which act as protein phospho-tyrosine binding domains, and mediate the interaction of this PTP with its substrates. This PTP is expressed primarily in hematopoietic cells, and functions as an important regulator of multiple signaling pathways in hematopoietic cells. This PTP has been shown to interact with, and dephosphorylate a wide spectrum of phospho-proteins involved in hematopoietic cell signaling, (e.g., the LYN-CD22-SHP-1 pathway). Multiple alternatively spliced variants of this gene, which encode distinct isoforms, have been reported. |
|||
Anti-Prohibitin Antibody [SR46-02] |
|||
| ET1602-31 | HUABIO | 100ul | EUR 231 |
|
Description: Prohibitin is an evolutionarily conserved protein that has antiproliferative activity. The gene encoding human prohibitin maps to chromosome 17q21 and is ubiquitously expressed. Prohibitin is a post-synthetically modified protein that is localized in the inner membrane of mitochondria, where it regulates the cell cycle by blocking the transition between the G1 and S phases, and on the plasma membrane of B cells, where it mediates B cell maturation. Prohibitin mRNA and protein levels are high in G1, decline during the S phase, rise again in G2 and decline in M phase, which suggests that prohibitin controls the cell cycle by using both transcriptional and posttranslational mechanisms. Prohibitin is also a potential tumor suppressor protein that binds to retinoblastoma (Rb) and subsequently inhibits the activity of E2F family members in response to specific signaling cascades. Prohibitin 2 is a repressor of estrogen receptor activity, and is required for somatic and germline differentiation in the larval gonad during embryonic development. Mutations in the Prohibitin genes are correlated with breast cancer development and/or progressionin more than 80% of the cell lines analyzed. |
|||
Anti-Survivin Antibody [SR44-02] |
|||
| ET1602-43 | HUABIO | 100ul | EUR 231 |
|
Description: Multitasking protein that has dual roles in promoting cell proliferation and preventing apoptosis .Component of a chromosome passage protein complex (CPC) which is essential for chromosome alignment and segregation during mitosis and cytokinesis .Acts as an important regulator of the localization of this complex; directs CPC movement to different locations from the inner centromere during prometaphase to midbody during cytokinesis and participates in the organization of the center spindle by associating with polymerized microtubules.Involved in the recruitment of CPC to centromeres during early mitosis via association with histone H3 phosphorylated at 'Thr-3' (H3pT3) during mitosis.The complex with RAN plays a role in mitotic spindle formation by serving as a physical scaffold to help deliver the RAN effector molecule TPX2 to microtubules .May counteract a default induction of apoptosis in G2/M phase .The acetylated form represses STAT3 transactivation of target gene promoters.May play a role in neoplasia. Inhibitor of CASP3 and CASP7.Essential for the maintenance of mitochondrial integrity and function. |
|||
Anti-GFP Antibody [SR48-02] |
|||
| ET1602-7 | HUABIO | 100ul | EUR 231 |
|
Description: Green fluorescence protein (GFP) is derived from the jellyfish Aequorea victoria, which emits green light (emission peak at a wavelength of 509 nm) when excited by blue light (excitation peak at a wavelength of 395 nm). GFP fluorescence is stable under fixation conditions and suitable for a variety of applications. It has been widely used as a reporter for gene expression, enabling researchers to visualize and localize GFP-tagged proteins within living cells without chemical staining. |
|||
Anti-Olig2 Antibody [SP07-02] |
|||
| ET1604-29 | HUABIO | 100ul | EUR 231 |
|
Description: The oligodendrocyte lineage-specific basic helix-loop-helix (OLIG) family of transcription factors include OLIG1-OLIG3, which differ in tissue expression. OLIG1 and OLIG2 are specifically expressed in nervous tissue as gene regulators of oligodendrogenesis. OLIG2 is more widely expressed in embryonic brain than OLIG1, while OLIG3 is primarily expressed in non-neural tissues. OLIG1 and OLIG2 interact with the Nkx-2.2 homeodomain protein, which is responsible for directing ventral neuronal patterning in response to graded Sonic hedgehog signaling in the embryonic neural tube. These interactions between OLIG proteins and Nkx-2.2 appear to promote the formation of alternate cell types by inhibiting V3 interneuron development. OLIG1 and OLIG2 are abundantly expressed in oligodendroglioma and nearly absent in astrocytomas. Therefore, OLIG proteins are candidates for molecular markers of human glial brain tumors, which are the most common primary malignancies of the human brain. |
|||
Anti-MSH6 Antibody [SP08-02] |
|||
| ET1604-39 | HUABIO | 100ul | EUR 231 |
|
Description: Multiple pathways promote short-sequence recombination (SSR) in Saccharomyces cerevisiae. When gene conversion is initiated by a double-strand break (DSB), any nonhomologous DNA that may be present at the ends must be removed before new DNA synthesis can be initiated. Removal of a 3' nonhomologous tail in S. cerevisiae depends on the nucleotide excision repair endonuclease Rad1/Rad10 and also on the mismatch repair proteins Msh2 and Msh3. Msh2 and Msh3, which function in mitotic recombination, recognize not only heteroduplex loops and mismatched basepairs, but also branched DNA structures with a free 3' tail. Msh2 and Msh6 form a protein complex required to repair mismatches generated during DNA replication. Yeast Msh2-Msh6 interact asymmetrically with the DNA through base-specific stacking and hydrogen bonding interactions and backbone contacts. The importance of these contacts decreases with increasing distance from the mismatch, implying that interactions at or near the mismatch are important for binding in a kinked DNA conformation. |
|||
Anti-ALDH1A1 Antibody [SY11-02] |
|||
| ET1605-24 | HUABIO | 100ul | EUR 231 |
|
Description: Aldehyde dehydrogenases (ALDHs) mediate NADP+-dependent oxidation of aldehydes into acids during the detoxification of alcohol-derived acetaldehyde; metabolism of corticosteroids, biogenic amines and neurotransmitters; and lipid peroxidation. ALDH1A1, also designated retinal dehydrogenase 1 (RalDH1 or RALDH1), aldehyde dehydrogenase family 1 member A1, aldehyde dehydrogenase cytosolic, ALDHII, ALDH-E1 or ALDH E1, is a retinal dehydrogenase that participates in the biosynthesis of retinoic acid (RA). There are two major liver isoforms of ALDH1 that can localize to cytosolic or mitochondrial space. The ALDH1A2 (RALDH2, RALDH2-T) gene produces three different transcripts and also catalyzes the synthesis of RA from retinaldehyde. ALDH1A3 (ALDH6, RALDH3, ALDH1A6) is a 37 kb gene that consists of 13 exons and produces a major transcript of approximately 3.5 kb most abundant in salivary gland, stomach and kidney. ALDH3A1 (stomach type, ALDH3, ALDHIII) forms a cytoplasmic homodimer that preferentially oxidizes aromatic aldehyde substrates. ALDH genes upregulate as a part of the oxidative stress response, and appear to be abundant in certain tumors that have an accelerated metabolism toward chemotherapy agents. |
|||
Anti-CDX2 Antibody [SY09-02] |
|||
| ET1605-4 | HUABIO | 100ul | EUR 231 |
|
Description: In common with the two other Cdx genes, CDX2 regulates several essential processes in the development and function of the lower gastrointestinal tract (from the duodenum to the anus) in vertebrates. In vertebrate embryonic development, CDX2 becomes active in endodermal cells that are posterior to the developing stomach.These cells eventually form the intestinal epithelium. The activity of CDX2 at this stage is essential for the correct formation of the intestine and the anus.CDX2 is also required for the development of the placenta. |
|||
Anti-CD63 Antibody [SY21-02] |
|||
| ET1607-2 | HUABIO | 100ul | EUR 231 |
|
Description: The tetraspanins are integral membrane proteins expressed on cell surface and granular membranes of hematopoietic cells and are components of multi-molecular complexes with specific integrins. The tetraspanin CD63 (also known as LAMP-3, Melanoma-associated antigen ME491, TSPAN30, MLA1 and OMA81H) is a lysosomal membrane glycoprotein that translocates to the plasma membrane after platelet activation. CD63 is expressed on activated platelets, monocytes and macrophages, and is weakly expressed on granulocytes, T cell and B cells. It is located on the basophilic granule membranes and on the plasma membranes of lymphocytes and granulocytes. CD63 is a member of the TM4 superfamily of leukocyte glycoproteins that includes CD9, CD37 and CD53, which contain four transmembrane regions. CD63 may play a role in phagocytic and intracellular lysosome-phagosome fusion events. CD63 deficiency is associated with Hermansky-Pudlak syndrome. |
|||
Anti-Paxillin Antibody [SY23-02] |
|||
| ET1607-22 | HUABIO | 100ul | EUR 231 |
|
Description: Paxillin is a focal adhesion phosphoprotein that is localized to the cytoskeleton. Phosphorylation of paxillin has been shown to occur in response to PDGF treatment, v-Src transformation or cross-linking of integrins. FAK (focal adhesion kinase) and PYK2 have been shown to phosphorylate paxillin. FAK phosphorylates paxillin specifically on Tyr 118 in vitro. However, FAK phosphorylation does not seem to be required for the recruitment of paxillin to cell adhesion sites. Paxillin may play a role in signal transduction, regulation of cell morphology and the recruitment of structural and signaling molecules to focal adhesions. It has been shown that the amount of paxillin is reduced in mitotic cells by proteolytic downregulation and that paxillin is alternatively phosphorylated on serine rather than on tyrosine and serine during mitosis. |
|||
Anti-CDK1 Antibody [SY26-02] |
|||
| ET1607-51 | HUABIO | 100ul | EUR 231 |
|
Description: Cdk1 is a small protein (approximately 34 kilodaltons), and is highly conserved. Cdk1 is comprised mostly by the bare protein kinase motif, which other protein kinases share. Cdk1, like other kinases, contains a cleft in which ATP fits. When bound to its cyclin partners, Cdk1 phosphorylation leads to cell cycle progression. Given its essential role in cell cycle progression, Cdk1 is highly regulated. Most obviously, Cdk1 is regulated by its binding with its cyclin partners. Cyclin binding alters access to the active site of Cdk1, allowing for Cdk1 activity; furthermore, cyclins impart specificity to Cdk1 activity. At least some cyclins contain a hydrophobic patch which may directly interact with substrates, conferring target specificity. Furthermore, cyclins can target Cdk1 to particular subcellular locations. |
|||
In conclusion, the novel model, using 8 laboratory and non-laboratory variables, performed well in risk stratifying patients with suspected chest pain regarding the presence of obstructive-CAD in the present Chinese cohort.